Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization
- PMID: 30248938
- PMCID: PMC6313374
- DOI: 10.3390/medsci6040082
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization
Abstract
Naltrexone and naloxone are classical opioid antagonists. In substantially lower than standard doses, they exert different pharmacodynamics. Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opioid-receptor blockade. Clinical reports of LDN have demonstrated possible benefits in diseases such as fibromyalgia, Crohn's disease, multiple sclerosis, complex-regional pain syndrome, Hailey-Hailey disease, and cancer. In a dosing range at less than 1 μg per day, oral naltrexone or intravenous naloxone potentiate opioid analgesia by acting on filamin A, a scaffolding protein involved in μ-opioid receptor signaling. This dose is termed ultra low-dose naltrexone/naloxone (ULDN). It has been of use in postoperative control of analgesia by reducing the need for the total amount of opioids following surgery, as well as ameliorating certain side-effects of opioid-related treatment. A dosing range between 1 μg and 1 mg comprises very low-dose naltrexone (VLDN), which has primarily been used as an experimental adjunct treatment for boosting tolerability of opioid-weaning methadone taper. In general, all of the low-dose features regarding naltrexone and naloxone have been only recently and still scarcely scientifically evaluated. This review aims to present an overview of the current knowledge on these topics and summarize the key findings published in peer-review sources. The existing potential of LDN, VLDN, and ULDN for various areas of biomedicine has still not been thoroughly and comprehensively addressed.
Keywords: Crohn’s disease; fibromyalgia; glia; low-dose naltrexone; naloxone; naltrexone; pain.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.Am J Hosp Palliat Care. 2019 Oct;36(10):907-912. doi: 10.1177/1049909119838974. Epub 2019 Mar 27. Am J Hosp Palliat Care. 2019. PMID: 30917675 Review.
-
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
-
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
-
Low dose naltrexone for induction of remission in Crohn's disease.Cochrane Database Syst Rev. 2014 Feb 21;(2):CD010410. doi: 10.1002/14651858.CD010410.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2018 Apr 01;4:CD010410. doi: 10.1002/14651858.CD010410.pub3. PMID: 24558033 Updated. Review.
-
Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.Brain Res. 2007 Sep 5;1167:31-41. doi: 10.1016/j.brainres.2007.06.058. Epub 2007 Jul 14. Brain Res. 2007. PMID: 17692296
Cited by
-
Enkephalins and Pain Modulation: Mechanisms of Action and Therapeutic Perspectives.Biomolecules. 2024 Jul 30;14(8):926. doi: 10.3390/biom14080926. Biomolecules. 2024. PMID: 39199314 Free PMC article. Review.
-
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.J Transl Med. 2024 Jul 5;22(1):630. doi: 10.1186/s12967-024-05412-3. J Transl Med. 2024. PMID: 38970055 Free PMC article. Review.
-
Low-dose naltrexone extends healthspan and lifespan in C. elegans via SKN-1 activation.iScience. 2024 May 8;27(6):109949. doi: 10.1016/j.isci.2024.109949. eCollection 2024 Jun 21. iScience. 2024. PMID: 38799567 Free PMC article.
-
Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target.Front Immunol. 2024 May 3;15:1264702. doi: 10.3389/fimmu.2024.1264702. eCollection 2024. Front Immunol. 2024. PMID: 38765011 Free PMC article.
-
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia.BMJ Open. 2024 May 13;14(5):e085272. doi: 10.1136/bmjopen-2024-085272. BMJ Open. 2024. PMID: 38740499 Free PMC article.
References
-
- Bihari B. Low-dose naltrexone for normalizing immune system function. Altern. Ther. Health Med. 2013;19:56–65. - PubMed
-
- Google Search of “Low-Dose Naltrexone” on March 7th 2018. [(accessed on 7 March 2018)]; Available online: www.google.com.
-
- CFS Pharmacy Shop 2018. [(accessed on 9 March 2018)]; Available online: https://www.cfspharmacy.pharmacy/human-medicine/naltrexone-low-dose-comp....
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials